Cargando…

BNT162b2 Vaccine Effectiveness against Omicron in Children 5 to 11 Years of Age

BACKGROUND: Limited evidence is available on the real-world effectiveness of the BNT162b2 vaccine against coronavirus disease 2019 (Covid-19) and specifically against infection with the omicron variant among children 5 to 11 years of age. METHODS: Using data from the largest health care organization...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cohen-Stavi, Chandra J., Magen, Ori, Barda, Noam, Yaron, Shlomit, Peretz, Alon, Netzer, Doron, Giaquinto, Carlo, Judd, Ali, Leibovici, Leonard, Hernán, Miguel A., Lipsitch, Marc, Reis, Ben Y., Balicer, Ran D., Dagan, Noa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Massachusetts Medical Society 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9258754/ https://www.ncbi.nlm.nih.gov/pubmed/35767475 http://dx.doi.org/10.1056/NEJMoa2205011

Ejemplares similares

Effectiveness of the BNT162b2mRNA COVID-19 vaccine in patients with hematological neoplasms in a nationwide mass vaccination setting
por: Mittelman, Moshe, et al.
Publicado: (2022)

Safety of the BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting
por: Barda, Noam, et al.
Publicado: (2021)

Effectiveness of BNT162b2 Vaccine against Delta Variant in Adolescents
por: Reis, Ben Y., et al.
Publicado: (2021)

Adverse Effects after BNT162b2 Vaccine and SARS-CoV-2 Infection, According to Age and Sex
por: Dagan, Noa, et al.
Publicado: (2021)

BNT162b2 Vaccine Booster and Mortality Due to Covid-19
por: Arbel, Ronen, et al.
Publicado: (2021)

Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study
por: Barda, Noam, et al.
Publicado: (2021)

BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting
por: Dagan, Noa, et al.
Publicado: (2021)

Effectiveness of the BNT162b2 Vaccine after Recovery from Covid-19
por: Hammerman, Ariel, et al.
Publicado: (2022)

Fourth Dose of BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting
por: Magen, Ori, et al.
Publicado: (2022)

Short-term Adverse Events After the Third Dose of the BNT162b2 mRNA COVID-19 Vaccine in Adults 60 Years or Older
por: Auster, Oren, et al.
Publicado: (2022)

Effectiveness of REGEN-COV antibody combination in preventing severe COVID-19 outcomes
por: Hayek, Samah, et al.
Publicado: (2022)

Myocarditis after BNT162b2 Vaccination in Israeli Adolescents
por: Witberg, Guy, et al.
Publicado: (2022)

BNT162b2 vaccine effectiveness in chronic kidney disease patients—an observational study
por: Bielopolski, Dana, et al.
Publicado: (2022)

Nirmatrelvir Use and Severe Covid-19 Outcomes during the Omicron Surge
por: Arbel, Ronen, et al.
Publicado: (2022)

Comparing COVID-19-related hospitalization rates among individuals with infection-induced and vaccine-induced immunity in Israel
por: Waxman, Jacob G., et al.
Publicado: (2022)

Effectiveness of first-generation severe acute respiratory syndrome coronavirus 2 mRNA vaccines against the Omicron variant
por: Dagan, Noa, et al.
Publicado: (2022)

Early effectiveness of BNT162b2 Covid-19 vaccine in preventing SARS-CoV-2 infection in healthcare personnel in six Israeli hospitals (CoVEHPI)
por: Katz, Mark A., et al.
Publicado: (2022)

External validation and comparison of three prediction tools for risk of osteoporotic fractures using data from population based electronic health records: retrospective cohort study
por: Dagan, Noa, et al.
Publicado: (2017)

Indirect protection of children from SARS-CoV-2 infection through parental vaccination
por: Hayek, Samah, et al.
Publicado: (2022)

The role of observational studies based on secondary data in studying SARS-CoV-2 vaccines
por: Barda, Noam, et al.
Publicado: (2022)

Developing a COVID-19 mortality risk prediction model when individual-level data are not available
por: Barda, Noam, et al.
Publicado: (2020)

Immunogenicity of Omicron BA.1-adapted BNT162b2 vaccines: randomized trial, 3-month follow-up
por: Barda, Noam, et al.
Publicado: (2023)

Myocarditis after Covid-19 Vaccination in a Large Health Care Organization
por: Witberg, Guy, et al.
Publicado: (2021)

Three-month follow-up of durability of response to the third dose of the SARS-CoV-2 BNT162b2 vaccine in adults aged 60 years and older: a prospective cohort study
por: Eliakim-Raz, Noa, et al.
Publicado: (2022)

BNT162b2 Protection against the Omicron Variant in Children and Adolescents
por: Price, Ashley M., et al.
Publicado: (2022)

Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization
por: Cele, Sandile, et al.
Publicado: (2021)

BNT162b2 mRNA COVID-19 vaccine three-dose safety and risk of COVID-19 in patients with myasthenia gravis during the alpha, delta, and omicron waves
por: Doron, Alon, et al.
Publicado: (2022)

Effectiveness of a bivalent mRNA vaccine booster dose to prevent severe COVID-19 outcomes: a retrospective cohort study
por: Arbel, Ronen, et al.
Publicado: (2023)

Effectiveness of BNT162b2 Vaccine against Omicron Variant in South Africa
por: Collie, Shirley, et al.
Publicado: (2021)

Protection by a Fourth Dose of BNT162b2 against Omicron in Israel
por: Bar-On, Yinon M., et al.
Publicado: (2022)

Evidence for increased breakthrough rates of SARS-CoV-2 variants of concern in BNT162b2-mRNA-vaccinated individuals
por: Kustin, Talia, et al.
Publicado: (2021)

Antibody Titers After a Third and Fourth SARS-CoV-2 BNT162b2 Vaccine Dose in Older Adults
por: Eliakim-Raz, Noa, et al.
Publicado: (2022)

MHC Haplotyping of SARS-CoV-2 Patients: HLA Subtypes Are Not Associated with the Presence and Severity of COVID-19 in the Israeli Population
por: Ben Shachar, Shay, et al.
Publicado: (2021)

Humoral Response to Pfizer BNT162b2 Vaccine Booster in Maintenance Hemodialysis Patients
por: Shashar, Moshe, et al.
Publicado: (2022)

Fourth BNT162b2 vaccination neutralization of omicron infection after heart transplantation
por: Peled, Yael, et al.
Publicado: (2022)

Effectiveness and Durability of the BNT162b2 Vaccine against Omicron Sublineages in South Africa
por: Collie, Shirley, et al.
Publicado: (2022)

Evaluation of Seropositivity Following BNT162b2 Messenger RNA Vaccination for SARS-CoV-2 in Patients Undergoing Treatment for Cancer
por: Massarweh, Amir, et al.
Publicado: (2021)

Six-Month Follow-up after a Fourth BNT162b2 Vaccine Dose
por: Canetti, Michal, et al.
Publicado: (2022)

Third BNT162b2 Vaccination Neutralization of SARS-CoV-2 Omicron Infection
por: Nemet, Ital, et al.
Publicado: (2021)

Effectiveness of the third dose of BNT162b2 vaccine on neutralizing Omicron variant in the Japanese population()
por: Kawasuji, Hitoshi, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ju5gclfd0i0gg22v1p0v7mjquj